Evorpacept (ALX148) in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma
DRUG: evorpacept|DRUG: pembrolizumab|DRUG: Cisplatin/Carboplatin; 5FU
Objective response rate per RECIST 1.1, Last randomized patient reaching at least 24 weeks of follow-up
Duration of response, Up to 36 months|Progression-free survival, Up to 36 months|Overall survival, Up to 36 months|Adverse events, Up to 36 months
This is a open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of evorpacept (ALX148) + pembrolizumab + 5FU + platinum and of pembrolizumab + 5FU + platinum in patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated for their advanced disease. The study comprises of an initial safety lead-in followed by a randomized portion.